Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome

Am J Hematol. 2015 Nov;90(11):1091-2. doi: 10.1002/ajh.24015. Epub 2015 Apr 29.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Bone Marrow / drug effects
  • Bone Marrow / pathology*
  • Castleman Disease / complications
  • Castleman Disease / diagnosis*
  • Castleman Disease / drug therapy
  • Castleman Disease / pathology
  • Histocytochemistry
  • Humans
  • Immunologic Factors / therapeutic use
  • Lymph Nodes / drug effects
  • Lymph Nodes / pathology
  • Male
  • Megakaryocytes / drug effects
  • Megakaryocytes / pathology*
  • Plasma Cells / drug effects
  • Plasma Cells / pathology
  • Primary Myelofibrosis / complications
  • Primary Myelofibrosis / diagnosis*
  • Primary Myelofibrosis / drug therapy
  • Primary Myelofibrosis / pathology
  • Remission Induction
  • Rituximab / therapeutic use
  • Treatment Outcome

Substances

  • Immunologic Factors
  • Rituximab